Loading stock data…
Larimar Therapeutics (LRMR)
$4.08+0.24 (+6.40%)
Market ClosedLast close Sep 8
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Larimar Therapeutics, Inc. in the Healthcare sector is trading at $4.08 with a market capitalization of $360M. Wall Street consensus targets $14.30 (10 analysts), implying a +250.9% move over the next 12 months. The stock is currently 37% below its 52-week high of $6.42, remaining 3.4% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +250.9% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$31.12M↑ | -$64.02M↓ | -$49.50M↓ | -$27.79M↑ | -$31.19M |
| Net Income | -$29.61M↑ | -$62.50M↓ | -$47.71M↓ | -$26.18M↑ | -$29.28M |
Peer Comparison
JNJUNHPFE
Fundamentals
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clini...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$360.47M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-105.04%
Volume
Today's trading volume
1.04M
Recent News
Larimar Therapeutics (LRMR) Submits Initial Module of BLA For Nomlabofusp Therapy
Larimar Therapeutics Inc. (NASDAQ:LRMR) is one of the 10 best stocks under $10 that could triple. On June 29, Larimar Therapeutics Inc. (NASDAQ:LRMR) filed the first module of its Biologics License Application (BLA) to the U.S. FDA to get its Nomlabofusp therapy approved on an accelerated basis. The company also plans to submit the other […]
LRMR Stock Edges Up After Hours After Director Purchases Shares Worth About $167,000
The shares were acquired in multiple transactions at prices ranging from $3.33 to $3.35 per share.
Here’s What Citi Thinks About Larimar Therapeutics (LRMR)
Larimar Therapeutics, Inc. (NASDAQ:LRMR) is one of the Best Small-Cap Growth Stocks to Invest In Now. Recently, on June 19, Samantha Semenkow, an analyst from Citi, maintained a Buy rating on Larimar Therapeutics, Inc. (NASDAQ:LRMR), with a price target of $14. The firm noted that the bullish sentiment is based on the company’s lead drug […]
LRMR Shares Hold Steady As Wall Street Optimism Offsets Drug Safety Concerns
H.C. Wainwright initiated coverage of Larimar with a ‘Buy’ rating and a $10 price target on Thursday.
Larimar Therapeutics Shares Drop Following Clinical Update and Regulatory Filing (LRMR)
Larimar Therapeutics (NASDAQ:LRMR) shares declined 17% on Monday after the company released new data from its ongoing open-label study and confirmed the submission of the first section of its rolling Biologics License Application (BLA) seeking accelerated approval for nomlabofusp as a treatment for Friedreich’s ataxia. The biotechnology company said the initial BLA module has been submitted to the U.